Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure

Joint Bone Spine

Volumn 76, Issue 4, 2009, Pages 424-426

  Announ, Nadia ^a   Palmer, Gaby ^a   Guerne, Pierre André ^a   Gabay, Cem ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Chondrocalcinosis; End stage renal failure; IL 1; Pseudogout

Indexed keywords

C REACTIVE PROTEIN; CALCIUM; CORTICOSTEROID; CREATININE; INTERLEUKIN 1BETA; PARATHYROID HORMONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; URIC ACID;

ABSENCE OF SIDE EFFECTS; AGED; ARTHRITIS; ARTICLE; CALCIUM BLOOD LEVEL; CASE REPORT; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPERTENSION; INFLAMMATION; JOINT ASPIRATION; KIDNEY FAILURE; MALE; PARATHYROID HORMONE BLOOD LEVEL; PROPHYLAXIS; PSEUDOGOUT; TREATMENT DURATION; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; CHONDROCALCINOSIS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; KIDNEY FAILURE, CHRONIC; MALE; TREATMENT OUTCOME;

EID: 67649798632     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2009.01.001     Document Type: Article

References (18)

1. Cheng H.F., and Harris R.C. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des 11 (2005) 1795-1804
2. Ly J., Gow P., and Dalbeth N. Colchicine prescribing and safety monitoring in patients with gout. N Z Med J 120 (2007) U2808
3. Announ N., and Guerne P.A. Treating difficult crystal pyrophosphate dihydrate deposition disease. Curr Rheumatol Rep 10 (2008) 228-234
4. Petrilli V., and Martinon F. The inflammasome, autoinflammatory diseases, and gout. Joint Bone Spine 74 (2007) 571-576
5. So A., De Smedt T., Revaz S., et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9 (2007) R28
6. McGonagle D., Tan A.L., Madden J., et al. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 58 (2008) 631-633
7. Rosenthal A.K. Update in calcium deposition diseases. Curr Opin Rheumatol 19 (2007) 158-162
8. Jacques C., Gosset M., Berenbaum F., et al. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam Horm 74 (2006) 371-403
9. Black R.A., Kronheim S.R., Cantrell M., et al. Generation of biologically active interleukin-1 beta by proteolytic cleavage of the inactive precursor. J Biol Chem 263 (1988) 9437-9442
10. Martinon F., Burns K., and Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-1beta. Mol Cell 10 (2002) 417-426
11. Martinon F., and Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117 (2004) 561-574
12. Liu Bryan R., Pritzker K., Firestein G., et al. TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J Immunol 174 (2005) 5016-5023
13. Arend W.P., Malyak M., Guthridge C.J., et al. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 16 (1998) 27-55
14. Burger D., Dayer J.M., Palmer G., et al. Is IL-1 a good therapeutic target in the treatment of arthritis?. Best Pract Res Clin Rheumatol 20 (2006) 879-896
15. Arend W.P., and Gabay C. Anakinra (interleukin-1 receptor antagonist). In: St Clair E.W., Pisetsky D.S., and Haynes B.F. (Eds). Rheumatoid arthritis (2004), Lippincott Williams and Wilkins, Philadelphia, PA 385-393
16. Chollet-Janin A., Finckh A., Dudler J., et al. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum 56 (2007) 688-692
17. Tran Doan T.H., Chevalier X., Leparc J.M., et al. Premature enthusiasm for the use of methotrexate for refractory chondrocalcinosis: comment on the article by Chollet-Janin, et al. Arthritis Rheum 58 (2008) 2210-2211
18. Seitz M. Molecular and cellular effects of methotrexate. Curr Opin Rheumatol 11 (1999) 226-232